Bailard Inc. Takes Position in Arrowhead Pharmaceuticals Inc (ARWR)

Bailard Inc. bought a new stake in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 35,000 shares of the biotechnology company’s stock, valued at approximately $671,000.

Several other hedge funds also recently bought and sold shares of the company. Vivo Capital LLC lifted its stake in Arrowhead Pharmaceuticals by 22.6% during the third quarter. Vivo Capital LLC now owns 2,328,475 shares of the biotechnology company’s stock worth $44,637,000 after purchasing an additional 428,475 shares during the last quarter. Blair William & Co. IL lifted its stake in Arrowhead Pharmaceuticals by 7.0% during the third quarter. Blair William & Co. IL now owns 67,580 shares of the biotechnology company’s stock worth $1,296,000 after purchasing an additional 4,410 shares during the last quarter. Credit Suisse AG lifted its stake in Arrowhead Pharmaceuticals by 15.1% during the third quarter. Credit Suisse AG now owns 82,739 shares of the biotechnology company’s stock worth $1,586,000 after purchasing an additional 10,843 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Arrowhead Pharmaceuticals by 26.1% during the third quarter. DekaBank Deutsche Girozentrale now owns 107,200 shares of the biotechnology company’s stock worth $1,544,000 after purchasing an additional 22,200 shares during the last quarter. Finally, FMR LLC bought a new stake in Arrowhead Pharmaceuticals during the third quarter worth about $37,922,000. Institutional investors own 63.33% of the company’s stock.

In other news, VP Peter Brian Leone sold 131,137 shares of the business’s stock in a transaction dated Friday, October 19th. The stock was sold at an average price of $13.49, for a total value of $1,769,038.13. Following the completion of the sale, the vice president now owns 160,000 shares of the company’s stock, valued at approximately $2,158,400. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Douglas B. Given sold 3,000 shares of the business’s stock in a transaction dated Friday, November 23rd. The shares were sold at an average price of $12.74, for a total value of $38,220.00. The disclosure for this sale can be found here. In the last three months, insiders sold 215,637 shares of company stock valued at $2,980,043. 4.60% of the stock is currently owned by corporate insiders.

NASDAQ ARWR opened at $13.13 on Friday. Arrowhead Pharmaceuticals Inc has a 1-year low of $3.01 and a 1-year high of $22.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.69 and a quick ratio of 8.69. The stock has a market capitalization of $1.19 billion, a PE ratio of -27.94 and a beta of 2.05.

Several equities research analysts have issued reports on the company. BidaskClub lowered Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 16th. Chardan Capital reaffirmed a “buy” rating and set a $17.50 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 13th. Piper Jaffray Companies reissued an “overweight” rating and issued a $25.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 4th. William Blair reissued an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 17th. Finally, Cantor Fitzgerald boosted their target price on Arrowhead Pharmaceuticals from $18.00 to $24.00 and gave the company an “overweight” rating in a research note on Thursday, October 4th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $21.45.

ILLEGAL ACTIVITY NOTICE: “Bailard Inc. Takes Position in Arrowhead Pharmaceuticals Inc (ARWR)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/12/08/bailard-inc-takes-position-in-arrowhead-pharmaceuticals-inc-arwr.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Featured Story: Trading Penny Stocks

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR).

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply